Evaluation of risk factors/prevalence of insulin resistance, diabetes mellitus, hypertension and central-obesity in people living with HIV/AIDS at the Bamenda Regional Hospital


  • Enoh Jude Eteneneng Cardio-Metabolic Health Research Group, Faculty of Natural Sciences, Walter Sisulu University, Mthatha 5117, South Africa
  • Ngu Felix Akum Department of Medical Laboratory Sciences. Faculty of Health Sciences, University of Buea, Buea , Cameroon


Insulin-resistance, HAART, Hyperglycemia, Central obesity


Despite the advancement and benefits of antiretroviral therapy in recent years since its introduction, it has also resulted in complications such as metabolic syndrome like insulin resistance. This study is aimed at determining the prevalence and risk factors of metabolic syndrome in people living with HIV/AIDS (on Highly Active Antiretroviral Therapy (HAART) and HAART-naïve) at the Bamenda Regional Hospital. 273 participants were consecutively recruited; 191 were HAART-exposed, and 82 were HAART-naïve. Anthropometric and blood pressure measurements were conducted under standard conditions. Fasting blood sugar, triglyceride, and High-density-lipoprotein cholesterol (HDLc), were determined spectrophotometrically. Chi-square (χ2) and odd ratios were used to compare the prevalence of the metabolic syndromes between cases and controls at a 99% confidence interval. The study recorded a prevalence of 24.2%, 3.66%, 38.1% and 39.56% for insulin resistance, hyperglycemia, hypertension, and central obesity, respectively. HAART-naïve were significantly about twice at risk of developing decreased HDL compared to the HAART-exposed group [OR 2.04; 95% CI 1.14-3.66; P=0.015]. However, HAART-treatment duration ≥10 years was significantly associated with hyperglycemia. The type of HAART regimen also showed a significant association with increased central obesity. It is evident from this study that the following risk factors of metabolic syndrome are common among HIV/AIDS patients: lower HDL, central obesity, alcohol consumption, smoking habits, and age≥50 years. This, therefore, highlights the importance of these patients regulating their lifestyle since there is a rising risk of developing metabolic syndromes among them.


A. Bowo-Ngandji, S. Kenmoe, J. T. Ebogo-Belobo, R. Kenfack-Momo, G. R. Takuissu, C. Kengne-Ndé, D. S. Mbaga, S. Tchatchouang, J. KenfackZanguim, R. L. Fogang, J. L. Ndzie Ondigui, G. I. Kame-Ngasse, J. N. Magoudjou-Pekam, M. W. Nguedjo, J. P. Assam Assam, D. E. Mandob, & J. L. Ngondi, ‘‘Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis’’, PLOS ONE 18 (2023) e0289155. https://doi.org/10.1371/journal.pone.0289155.

H. E. Ergin, E. E. Inga, T. Z. Maung, M. Javed, & S. Khan, ‘‘HIV, Antiretroviral Therapy and Metabolic Alterations: A Review’’, Cureus 12 (2020) 8059. https://doi.org/10.7759/cureus.8059.

O. A. Ekun, E. O. Fasela, D. A. Oladele, G. O. Liboro, & T. Y. Raheem, ‘‘Risksofcardio-vasculardiseasesamonghighlyactiveantiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria’’,the Pan African Medical Journal 38 (2021) 26791. https://doi.org/10.11604/pamj.2021.38.206.26791.

F. F. Abou Hassan, M. A. Bou Hamdan, K. E. Asmar, J. E. Mokhbat, & N. M. Melhem. ‘‘Trends & predictors of non-AIDS comorbidities among people living with HIV and receiving antiretroviral therapy in Lebanon’’, Medicine 101 (2022) e29162. https://doi.org/10.1097/MD.0000000000029162

E. Ojong, B. Iya, J. Djeufouata, F. Ndeh, V. Njongang, M. Etukudo, C. Usoro, & J. Ekpo, ‘‘Metabolic syndrome and its components among HIV/AIDS patients on Antiretroviral Therapy and ART-Naïve Patients at the University of Calabar Teaching Hospital, Calabar, Nigeria’’, African Health Sciences 22 (2022) 410. https://doi.org/10.4314/ahs.v22i1.50.

D. Y. Lu, H. Y. Wu, N. S. Yarla, B. Xu, J. Ding, & T. R. Lu, ‘‘HAART in HIV/AIDS Treatments: Future Trends’’, Infectious disorders drug targets 18 (2018) 15. https://doi.org/10.2174/1871526517666170505122800.

J. E. Enoh, F. N. Cho, F. P. Manfo, S. E. Ako, & E. A. Akum, ‘‘Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-CoinfectedPatientsonTreatmentinFakoDivision, SouthwestRegion of Cameroon’’, BioMed Research International 2020 (2020) 9631731. https://doi.org/10.1155/2020/9631731.

J. J. Noubiap, J. J. Bigna, J. R. Nansseu, U. F. Nyaga, E. V. Balti, J. B. Echouffo-Tcheugui, A. P. Kengne, ‘‘Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis’’, Lancet Glob Health 6 (2018) e998. https://doi.org/10.1016/S2214-109X(18)30275-4.

G. Yousefzadeh, A. Sayyadi, H. Najafipour, V. Sabaghnejad, & S.Pezeshki, ‘‘Comparing the association of two metabolic syndrome definitions, NCEP ATP III and IDF, with the risk of developing atherosclerotic cardiovascular disease: An analytical cross-sectional study’’, Endocrinology, diabetes & metabolism 7 (2024) e468. https://doi.org/10.1002/edm2.468.

M. Woldu, O. Minzi, & E. Engidawork, ‘‘Prevalence of cardiometabolic syndrome in HIV-infected persons: A systematic review’’, Journal of Diabetes and Metabolic Disorders 19 (2020) 1671. https://doi.org/10.1007/s40200-020-00552-x.

E. Bowman, N. T. Funderburg, ‘‘Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection’’, Curr HIV/AIDS Rep 16 (2019) 214. https://doi.org/10.1007/s11904-019-00442-9.

G. H. da Cunha, K. B. Franco, M. T. G. Galvão, M. A. C. Lima, M. S. M. Fontenele, L. R. Siqueira, A. K. L. Ramalho & F. V. Fechine, ‘‘Diabetes mellitus in people living with HIV/AIDS: prevalence and associated risk factors’’, AIDS care 32 (2020) 600. https://doi.org/10.1080/09540121.2019.1695727.

T. Borkowska, N. Chkhartishvili, E. Karkashadze, O. Chokoshvili, P. Gabunia, L. Sharvadze & T. Tsertsvadze, ‘‘The prevalence of hyperglycemia and its impact on mortality among people living with HIV in Georgia’’, PloS one 17 (2022) e0276749. https://doi.org/10.1371/journal.pone.0276749.

D. M. Umar, & P. Naidoo, ‘‘Prevalence and predictors of diabetes mellitus among persons living with HIV: A retrospective cohort study conducted in 4 public healthcare facilities in KwaZulu-Natal’’, BMC Public Health bf21 (2021) 288. https://doi.org/10.1186/s12889-021-10318-6.

Michaela Murphy: ‘‘What to Know About HIV and Diabetes’’. (Accessed Feb 2024). https://www.healthline.com/health/hiv-aids/hiv-aids-and-diabetes.

A. Dzudie, D. Hoover, H. Y. Kim, R. Ajeh, A. Adedimeji, Q. Shi, Pefura W. Yone, D. Nsame Nforniwe, K. Thompson Njie, A. Pascal Kengne, P. V. Ebasone, B. Barche, Z. K. Bissek Anne Cecile, D. Nash, M. Yotebieng & K. Anastos, ‘‘Hypertension among people living with HIV/AIDS in Cameroon: A cross-sectional analysis from Central Africa International Epidemiology Databases to Evaluate AIDS’’, PloS one 16 (2021) e0253742. https://doi.org/10.1371/journal.pone.0253742.

S. Fahme, G. S. Bloomfield, & R. Peck, ‘‘Hypertension in Hiv-infected Adults: Novel pathophysiologicmechanisms’’, Hypertension72(2018) 44. https://doi.org/10.1161/HYPERTENSIONAHA.118.10893.

S. K. Masenga, & A. Kirabo, ‘‘Hypertensive heart disease: risk factors, complications and mechanisms’’, frontiers in cardiovascular medicine 10 (2023) 1205475. https://doi.org/10.3389/fcvm.2023.1205475.

G. Lubega, B. Mayanja, J. Lutaakome, A. Abaasa, R. Thomson, & C. Lindan, ‘‘Prevalence and factors associated with hypertension among people living with HIV/AIDS on antiretroviral therapy in Uganda’’, The Pan African Medical Journal 38 (2021) 28034. https://doi.org/10.11604/pamj.2021.38.216.28034.

S. Kumar & D. K. Dhanwal, ‘‘Central obesity & dyslipidemia in HIV patients on antiretroviral therapy’’, The Indian Journal of Medical Research 148 (2018) 366. https://doi.org/10.4103/ijmr.IJMR_1190_18.

A. A. Verhaegen & L. F. Van Gaal, ‘‘Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function—Mechanisms and Possible Therapeutic or Preventive Measures: an Update’’, Curr Obes Rep 10 (2021) 1. https://doi.org/10.1007/s13679-020-00419-5.

Prevalence of Metabolic syndrome based on study groups.



How to Cite

Evaluation of risk factors/prevalence of insulin resistance, diabetes mellitus, hypertension and central-obesity in people living with HIV/AIDS at the Bamenda Regional Hospital. (2024). Recent Advances in Natural Sciences, 2(2), 101. https://doi.org/10.61298/rans.2024.2.2.101

How to Cite

Evaluation of risk factors/prevalence of insulin resistance, diabetes mellitus, hypertension and central-obesity in people living with HIV/AIDS at the Bamenda Regional Hospital. (2024). Recent Advances in Natural Sciences, 2(2), 101. https://doi.org/10.61298/rans.2024.2.2.101